Poster ABCL-755

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma

Paolo F Caimi[1], Scott Huntington[2], Sean Landrette[3], Sheryl M Gough[3], Michael Lachowicz[3], Elena Kostenko[3], Eric Zhi[3], Edward Chan[3], Matthew Matasar[4]

Presenter: Meghan Colasanto[3]

[1]Cleveland Clinic, Cleveland, OH, USA; [2]Yale School of Medicine, New Haven, CT, USA; [3]Arvinas Operations, Inc., New Haven, CT, USA; [4]Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Objective

- To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ARV-393, a PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 (BCL6) degrader, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) or nodal T-follicular helper cell lymphoma angioimmunoblastic-type (nTFHL-AI), also known as angioimmunoblastic T-cell lymphoma

Background

- NHL represents a biologically and clinically diverse group of hematologic malignancies originating from B cells, T cells, and/or natural killer cells, with those of B-cell origin constituting approximately 80%–85% of all NHL cases[1]
- The BCL6 transcription factor is a key oncogenic driver of B-cell lymphomagenesis, and deregulated BCL6 expression is a common feature of diffuse large B-cell lymphoma,[2-6] the most common type of NHL[1]
- BCL6 is also implicated in nTFHL-AI
  - BCL6 is a lineage-defining transcription factor of T-follicular helper cells, thought to be the cell of origin for nTFHL-AI[7,8]
  - Human and murine nTFHL-AI tumor cells express BCL6, and its continued expression was required for tumor growth in a mouse model of nTFHL-AI[9]
- ARV-393 is an orally administered PROTAC BCL6 degrader that harnesses the ubiquitin-proteasome system to induce degradation of BCL6[10,11]
- ARV-393 is a bifunctional molecule consisting of a BCL6-binding domain joined by a linker to an E3 ubiquitin ligase–binding domain
- Formation of this trimer complex induces ubiquitination and subsequent degradation of BCL6 by the proteasome (**Figure 1**)
- In preclinical studies, ARV-393 induced rapid and robust degradation (>90%) of BCL6 in NHL cell lines and demonstrated substantial tumor growth inhibition in xenograft models, supporting further investigation in patients with NHL[11] (**Figure 2**)

Figure 1: Mechanism of action of ARV-393



[a]General PROTAC protein degrader is shown.
BCL6=B-cell lymphoma 6; PROTAC=PROteolysis TArgeting Chimera.

Figure 2: (A) Antitumor activity of ARV-393 in the OCI-Ly1 cell line xenograft model and (B) BCL6 levels at takedown 24 hours post dose[11]



****P<0.0001 vs vehicle. ARV-393 was administered for 23 consecutive days.
BCL6=B-cell lymphoma 6; BID=twice daily; GAPDH=glyceraldehyde 3-phosphate dehydrogenase; QD=once daily; TGI=tumor growth inhibition.

Study Design

- This open-label, first-in-human, phase 1, dose-escalation study (NCT06393738) in adult patients with relapsed/refractory NHL is evaluating the safety, tolerability, PK, PD, and preliminary antitumor activity of ARV-393 (**Figure 3**)
- Eligible patients have relapsed/refractory mature B-cell NHL and ≥2 prior systemic therapies, or histologically confirmed nTFHL-AI that has recurred or progressed following standard of care therapy (**Table 1**)
- Key outcome measures are shown in **Table 2**

Figure 3: Study schema



NHL=non-Hodgkin lymphoma; nTFHL-AI=nodal T-follicular helper cell lymphoma angioimmunoblastic-type.

Table 1: Key eligibility criteria

Inclusion criteria	Exclusion criteria
• Adults aged ≥18 years • Relapsed/refractory mature B-cell NHL and ≥2 prior systemic therapies, or histologically confirmed nTFHL-AI that has recurred or progressed following standard of care therapy • ≥1 measurable lesion at study entry • ECOG performance status of 0 or 1 • Freshly biopsied or archival tumor tissue available • Adequate organ function	• Prior allogeneic stem cell transplant or solid organ transplantation • Autologous stem cell transplant ≤100 days and previous CAR T-cell therapy ≤60 days prior to cycle 1, day 1 of ARV-393 treatment • Significant acute or chronic medical illness, including hypereosinophilic syndrome, active interstitial lung disease or pneumonitis, or active or uncontrolled infection

CAR=chimeric antigen receptor; ECOG=Eastern Cooperative Oncology Group; NHL=non-Hodgkin lymphoma; nTFHL-AI=nodal T-follicular helper cell lymphoma angioimmunoblastic-type.

Table 2: Key outcome measures

Primary objective	Primary endpoints
• Evaluate the safety and tolerability of ARV-393	• DLTs during cycle 1 • TEAEs including incidence, severity, seriousness, and relationship to study drug • Changes from baseline in vital signs, laboratory parameters, and ECG parameters • Grade 3/4 clinical laboratory abnormalities
Secondary objectives	**Secondary endpoints**
• Evaluate the PK profile of multiple ARV-393 doses	• Plasma concentration of study drug (AUC) • PK parameters of study drug (C_{max}, C_{min}, CL/F, T_{max}, and Vd/F)
• Assess preliminary antitumor activity of ARV-393	• ORR[a] by investigator assessment • CRR[b] by investigator assessment • DOR by investigator assessment

[a]The proportion of participants achieving a complete response or partial response according to the Lugano response criteria for NHL.[12]
[b]The proportion of participants achieving a complete response according to the Lugano response criteria for NHL.[12]
AUC=area under the plasma concentration time-curve; CL/F=clearance/bioavailability; C_{max}=maximum observed serum drug concentration; C_{min}=minimum observed serum drug concentration; CRR=complete response rate; DLT=dose-limiting toxicity; DOR=duration of response; ECG=electrocardiogram; ORR=objective response rate; PK=pharmacokinetic; TEAE=treatment-emergent adverse event; T_{max}=time taken to reach C_{max}; Vd/F=volume of distribution/bioavailability.

Study Status

- Enrollment is ongoing
- To view currently recruiting sites, please scan the QR code to visit ClinicalTrials.gov (NCT06393738)

References

1. B-cell lymphoma. MD Anderson Center. Accessed May 14, 2024. https://www.mdanderson.org/cancer-types/non-hodgkin-lymphoma/b-cell-lymphoma.html
2. Basso K, et al. Immunol Rev. 2012;247(1):172-83.
3. Pasqualucci L, et al. Blood. 2003;101(8):2914-23.
4. Lossos IS, et al. Leukemia. 2002;16(9):1857-62.
5. Cattoretti G, et al. Cancer Cell. 2005;7(5):445-55.
6. Green M, et al. Nat Commun. 2014;5:3904.
7. Choi J, et al. Nat Immunol. 2020;21(7):777-89.
8. Nurieva RI, et al. Science. 2009;325(5943):1001-5.
9. Witalis M, et al. Blood Adv. 2020;4(5):868-79.
10. Sherman D, et al. Presented at AACR Annual Meeting; April 5–10, 2024; San Diego, CA, USA.
11. Gough SM, et al. Presented at EHA Hybrid Congress. June 13–16, 2024; Madrid, Spain. Poster P1256.
12. Cheson BD, et al. J Clin Oncol. 2014;32(27):3059-68.

Acknowledgments

This study is sponsored by Arvinas, Inc. Medical writing was provided by Danielle Shepherd, PhD, of Red Nucleus and was funded by Arvinas Operations, Inc. Used with permission from Elsevier Science & Technology Journals, from Phase 1 study of ARV-393, a PROTAC BCL6 degrader, in advanced non-Hodgkin lymphoma, Caimi P, et al, *Blood*, 144, 2024; permission conveyed through Copyright Clearance Center, Inc.

Contact

Meghan Colasanto; Meghan.Colasanto@arvinas.com